[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity
Rhea-AI Filing Summary
PTC Therapeutics, Inc. (PTCT) reported insider activity by its Chief Technical Operations Officer. On 11/24/2025, the executive exercised several stock options to buy common stock at exercise prices of $18.01 and $33.02 per share and, on the same date, sold corresponding shares of common stock in multiple transactions at weighted average prices around $80 per share, with specific ranges disclosed for each sale.
The transactions were carried out under a written Rule 10b5-1 trading plan adopted on December 10, 2024, which is intended to provide an affirmative defense for pre-planned trades. Following the reported transactions, the executive beneficially owned 100,625 shares of PTCT common stock directly and an additional 6,179 shares indirectly through a spouse. Certain stock options reported in the filing are noted as currently exercisable, with stated expiration dates in 2028 and 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 1,900 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 1,650 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 4,715 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 21,206 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 6,101 | $0.00 | -- |
| Exercise | Common Stock | 1,900 | $18.01 | $34K |
| Sale | Common Stock | 1,900 | $80.14 | $152K |
| Exercise | Common Stock | 1,650 | $33.02 | $54K |
| Sale | Common Stock | 1,650 | $80.14 | $132K |
| Exercise | Common Stock | 4,715 | $18.01 | $85K |
| Sale | Common Stock | 4,715 | $80.15 | $378K |
| Exercise | Common Stock | 21,206 | $33.02 | $700K |
| Sale | Common Stock | 21,206 | $80.19 | $1.70M |
| Exercise | Common Stock | 6,101 | $33.02 | $201K |
| Sale | Common Stock | 6,101 | $80.17 | $489K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.14 to $80.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.56 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable.
